Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
can i take semaglutide before surgery and After Photos: Weight Loss Results Update on an ORAL Sale: Anniversary Sale 2026 Location:CANADA
Update on an ORAL MED for obesity and diabetes!
No, weight loss injections are contraindicated in people with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, during pregnancy and breastfeeding, and should be used with caution in those with severe renal impairment, history of pancreatitis, or diabetic retinopathy
Sale: Anniversary Sale 2026
Location:CANADA
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI ≥30 or ≥27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
